• Abdominal Chemotherapy Perfusion Effective on Treatment-resistant, Recurrent OC in Phase 2 Study
  • FDA Gives Priority Review to Lynparza as First-line Maintenance Therapy for Advanced Ovarian Cancer
  • Docetaxel Nanoparticle CPC634 in Phase 2 Trial for Platinum-resistant OC
  • Zejula Leads to Fewer Side Effects Than Previously Reported, Real-world Study Suggests
  • Adding GEN-1 to Standard Chemotherapy Halts Advanced Ovarian Cancer Progression, Phase 1b Trial Shows
  • Compugen, Bristol-Myers Squibb Collaborating to Test COM701, Opdivo Combo for Ovarian, Other Cancers
  • Cancer Cells from Fallopian Tube Communicate with Healthy Ovaries to Promote Cancer Growth, Researchers Find
  • Five Prime’s Phase 1 Trial Begins FPA150 Dosing Among Solid Tumor Patients
  • Lynparza Maintenance Delays Progression in Ovarian Cancer Patients by 3 Years, Phase 3 Trial Shows
  • First Patient Dosed in Phase 1 Trial of MCY-M11 in Ovarian Cancer, Peritoneal Mesothelioma
  • Carrick Acquires Rights to CT900, Plans New Trial in Ovarian Cancer Patients
  • Tina’s Wish Annual Benefit Dinner Raises $2 Million for Ovarian Cancer Research